The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ELCC 2022 | Chemotherapy in combination with immunotherapy for the treatment of metastatic thymic carcinoma
Nicolas Girard, MD, PhD, Institut Curie, Paris, France, talks on the challenge of treating metastatic thymic carcinoma and comments on a case report of a patient with metastatic thymic adenocarcinoma being treated with chemotherapy in combination with immunotherapy (IO). Usually this patient population is treated with first-line chemotherapy, with a second-line choice of chemotherapy, antiangiogenic agents or immune checkpoint inhibitors. Prof. Girard discusses using a combined approach, rather than the standard of care of a sequential approach, to treat a patient with metastatic thymic adenocarcinoma in the third metastatic line, providing results which may be of significant value in the development of future clinical trials for thymic carcinoma. This interview took place during the virtual European Lung Cancer Congress 2022.
